Evidence map›Paper›PMID 40491369›Full record

ArticleCurrent Alzheimer research2025

Association of Brain and Ventricular Boundary Shift Integral Measurements with CSF Biomarkers: A Case-Control Study.

Seyedeh Fahimeh Hosseini, Parastoo Akbarabadi, Fatemeh Noorani, Danial Kazemi, Hamidreza Sadeghsalehi, Mohammadtaghi Fattahpour, Mohammad Hosein Sheybani-Arani, Masoud Noroozi, Ali Kazemi, Alzheimer's Disease Neuroimaging Initiative

Abstract read
PubMed Publisher
In one paragraph

Article in Current Alzheimer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Seyedeh Fahimeh HosseiniMechanical Engineering Department, Sharif University of Technology, Teymouri Square, Tarasht, Postal Code: 1458889694, Tehran, Iran.
Parastoo AkbarabadiDepartment of Genetics, Faculty of Biological Science, Tarbiat Modares University, Jalal AleAhmad Street, Nasr Street, Postal Code: 14115111, Tehran, Iran.
Fatemeh NooraniFaculty of Medicine, Babol University of Medical Sciences, Ganj Afrooz Street, Postal Code: 4717647745, Babol, Mazandaran, Iran.
Danial KazemiStudent Research Committee, Isfahan University of Medical Sciences, Hezar Jerib Street, Postal Code: 8174673461, Isfahan, Iran.
Hamidreza SadeghsalehiDepartment of Artificial Intelligence in Medical Sciences, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Shahid Hemmat Highway, Postal Code: 1449614535, Tehran, Iran.
Mohammadtaghi FattahpourFaculty of Medicine, Tehran University of Medical Sciences, Pour Sina St, Postal Code: 1416634793, Tehran, Iran.
Mohammad Hosein Sheybani-AraniClinical Research Development Center of Shahid Mohammadi Hospital, Faculty of Medicine, Hormozgan University of Medical Sciences, Jomhuri Eslami Boulevard, Postal Code: 7919915519, Bandar Abbas, Iran.
Masoud NorooziDepartment of Biomedical Engineering, Faculty of Engineering, University of Isfahan, Azadi Square, Postal Code: 817467344, Isfahan, Iran.
Ali KazemiMedical Physics and Biomedical Engineering Department, Faculty of Medicine, Tehran University of Medical Sciences, Pour Sina St, Postal Code: 1416634793, Tehran, Iran.
Alzheimer's Disease Neuroimaging Initiative

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThis study seeks to examine the relationship between cerebrospinal fluid (CSF) biomarkers (Aβ1-42, Phospho-Tau181p, Total-Tau) and brain volumetric changes measured by Brain Shift Integral (BSI) in Alzheimer's disease (AD) spectrum. We explore the potential of BSI as a complementary, non-invasive tool for early diagnosis and progression monitoring of AD.

backgroundAD is a neurodegenerative disorder marked by amyloid plaques and tau tangles, leading to cognitive decline. CSF biomarkers are key indicators of AD pathology, but their integration with imaging metrics like BSI could enhance early diagnosis. BSI quantifies brain volume changes via MRI, offering valuable insights into neurodegeneration across the AD spectrum.

objectivesThe current study explores the use of BSI and CSF biomarkers for the early detection of Alzheimer's disease.

methodsThis study utilized data from the ADNI database, including CSF biomarkers (Aβ1-42, t-tau, ptau181) and BSI measurements from baseline and month 24 visits. Spearman correlations were performed to assess associations between biomarkers and brain volumetric changes. Linear regression models were used to examine the predictive value of biomarkers on BSI, controlling for potential confounders.

resultsA total of 239 participants were included in the study, comprising 94 cognitively normal (CN) individuals, 104 with mild cognitive impairment (MCI), and 41 with AD. Significant negative correlations were observed between Aβ1-42 and both BBSI and VBSI in MCI at baseline (p=0.013) and 24 months (p=0.018), as well as between Aβ1-42 and VBSI in CN at baseline (p=0.039) and 24 months (p=0.033). In MCI, p-tau181 was positively correlated with BBSI (p=0.013) and VBSI (p=0.030) at baseline and with BBSI at 24 months (p=0.013). Linear regression analysis confirmed that Aβ1-42 and p-tau181 significantly predicted BSI measures in MCI (R DISCUSSION: This study underscores the role of CSF biomarkers-particularly Aβ1-42 and p-tau181-in detecting early brain atrophy across the Alzheimer's disease spectrum, with limited utility in advanced stages. The findings highlight the importance of early intervention and support the integration of CSF biomarkers and BSI as diagnostic tools for monitoring disease progression and staging.

conclusionThe application of the BSI is pivotal for monitoring brain volume alterations and their association with CSF biomarkers.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBrainCerebral VentriclesPeptide FragmentsAgedAged, 80 and overBiomarkersCase-Control StudiesCognitive DysfunctionDisease ProgressionFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersPeptide Fragmentstau ProteinsAlzheimer's diseaseboundary shift integralbrain volume alterationsCSF biomarkersmild cognitive impairment.β-amyloid

Identifiers

PMID40491369

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.